<DOC>
	<DOCNO>NCT02246699</DOCNO>
	<brief_summary>The prevalence overweight obesity get important develop well emerge country . It define accord degree fat storage measurement fat mass . No clinical study conduct far intend use KiOnutrime®-Cs , fungal chitosan mycelium non-genetically modified Aspergillus niger . KiOnutrime®-Cs recognize substantially equivalent animal chitosan . The purpose clinical trial determine KiOnutrime®-Cs-containing medical device , CE-marked medical device manufacture KitoZyme , effect body weight reduction 3 month intake overweight obese men woman . Furthermore , effect anthropometric measurement , body fat mass percentage , serum lipid safety parameter investigate .</brief_summary>
	<brief_title>Efficacy Safety Fungal Chitosan Body Weight Reduction Overweight Obesity Volunteers</brief_title>
	<detailed_description>The study duration per subject 3 month 1 week maximum . Subjects screen visit V1 start 1-week run-in period , subject ingest 2 capsule placebo 3 time day . The subject randomize receive investigational medical device placebo ( 1:1 ) 3 month product intake period .</detailed_description>
	<mesh_term>Obesity</mesh_term>
	<mesh_term>Overweight</mesh_term>
	<mesh_term>Body Weight</mesh_term>
	<mesh_term>Weight Loss</mesh_term>
	<mesh_term>Chitosan</mesh_term>
	<criteria>Males females volunteer , able read write . Subject 25 ≤ Body Mass Index ≤ 35 kg/m² . Subject good physical condition base subject 's interview clinical exam perform Investigator . Subject stable body weight ( &lt; 5 % variation ) within last 3 month prior screen ( base interview ) . Written inform consent provide prior screen , receive understand subject information . Subject willing lose weight . Subject accept follow diet lifestyle instruction throughout study . Subject willing take study capsule three time day 3 month 1 week undergo studyrelated procedure . Registered French Social Security , agreement French law biomedical experimentation . Smoker former smoker stop within 2 month prior screen visit . Subject history alcohol drug abuse . Subject physical activity 3 hour per week . Subject sensitivity allergy product use within clinical trial . Subject history eat disorder ( anorexia nervosa , bulimia nervosa ) . Subject use weight reduction treatment product last 3 month prior screen visit . Subject significant gastrointestinal disease ( e.g . coeliac disease , pancreatitis ) , sign intestinal obstruction medical history constipation . Intake chronic medication could interfere study parameter ( weight , appetite , satiety , lipid blood level , glycemia , gastrointestinal function ) , effect digestion absorption nutrient , except oestroprogestative progestative contraception start least three month screen visit . Female subject planning pregnancy , pregnant breastfeeding . Female subject without efficient contraceptive method . Subject history bariatric surgery . Subject know systemic disease cancer , human immunodeficiency virus ( HIV ) seropositivity . Subject type 1 type 2 diabetes mellitus . Subject history significant medical surgical event require hospitalization 3 month prior screen visit . Subject , schedule exam us barium , radioisotope injection , oral intravenous contrast material within 2 week prior screen visit study . Participation clinical trial simultaneously and/or within 1 month prior screen visit . Subject donate blood blood product within previous month prior screen plan donate blood blood product time trial 3 month follow end study . Subject judge unlikely comply study product intake ( screen compliance &lt; 80 % ) diet lifestyle instruction .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>obesity</keyword>
	<keyword>overweight</keyword>
	<keyword>chitosan</keyword>
	<keyword>fungal chitosan</keyword>
	<keyword>weight management</keyword>
</DOC>